Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review)

Oncology Letters

Volumn 6, Issue 2, 2013, Pages 295-305

  Zhou, Jichun ^a   Teng, Rongyue ^a   Wang, Qinchuan ^a   Xu, Chenpu ^a   Guo, Jufeng ^a   Yuan, Chao ^a   Shen, Jianguo ^a   Hu, Wenxian ^a   Wang, Linbo ^a   Xie, Shuduo ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Breast cancer; Endocrine resistance; miRNAs

Indexed keywords

ARGONAUTE 2 PROTEIN; CYCLIN B1; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; LETROZOLE; MICRORNA; MICRORNA 101; MICRORNA 200C; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 26A; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; SMAD2 PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR EZH2;

3' UNTRANSLATED REGION; BREAST CANCER; CANCER HORMONE THERAPY; CELL PROLIFERATION; GENE EXPRESSION; GENETIC REGULATION; HORMONE RESISTANCE; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; PERSONALIZED MEDICINE; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 84879495313     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1405     Document Type: Review

References (78)

1. No authors listed: Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467, 1998.
2. Lau NC, Lim LP, Weinstein EG and Bartel DP: An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditiselegans. Science 294: 858-862, 2001.
3. Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T: Identification of novel genes coding for small expressed RNAs. Science 294: 853-858, 2001.
4. Lee RC and Ambros V: An extensive class of small RNAs in Caenorhabditis elegans. Science 294: 862-864, 2001.
5. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
6. Bartel DP and Chen CZ: Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 5: 396-400, 2004.
7. Ventura A and Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell 136: 586-591, 2009.
8. Iorio MV, Ferracin M, Liu CG, etal: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
9. Miller TE, Ghoshal K, Ramaswamy B, etal: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903, 2008.
10. Xin F, Li M, Balch C, etal: Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 25: 430-434, 2009.
11. Clark GM, Osborne CK and McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2: 1102-1109, 1984.
12. Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999.
13. No authors listed: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 339: 1-15, 1992.
14. El-Ashry D, Miller DL, Kharbanda S, Lippman ME and Kern FG: Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15: 423-435, 1997.
15. Osborne CK: Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. Endocr Relat Cancer 6: 271-276, 1999.
16. Howell A, Osborne CK, Morris C and Wakeling AE: ICI 182,780 (Faslodex): development of a novel, 'pure' antiestrogen. Cancer 89: 817-825, 2000.
17. Buzdar AU: Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist8: 335-341, 2003.
18. Hutcheson IR, Knowlden JM, Madden TA, etal: Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 81: 81-93, 2003.
19. Osborne CK, Pippen J, Jones SE, etal: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386-3395, 2002.
20. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
21. Baum M, Buzdar AU, Cuzick J, etal; ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002.
22. Mouridsen H, Gershanovich M, Sun Y, etal: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21: 2101-2109, 2003.
23. Massarweh S and Schiff R: Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res 13: 1950-1954, 2007.
24. Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9: 631-643, 2009.
25. Huber-Keener KJ, Liu XP, Wang Z, etal: Differential gene expression in Tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data. PLoS One 7: e41333, 2012.
26. Inui M, Martello G and Piccolo S: MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 11: 252-263, 2010.
27. Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
28. Wightman B, Ha I and Ruvkun G: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75: 855-862, 1993.
29. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
30. Betel D, Koppal A, Agius P, Sander C and Leslie C: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 11: R90, 2010.
31. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
32. O'Day E and Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12: 201, 2010.
33. Masri S, Liu Z, Phung S, Wang E, Yuan YC and Chen SA: The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat124: 89-99, 2010.
34. Lu J, Getz G, Miska EA, etal: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
35. Tian W, Chen J, He H and Deng Y: MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. Clin Transl Oncol 15: 335-342, 2013.
36. Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688, 2007.
37. Tavazoie SF, Alarcón C, Oskarsson T, etal: Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147-152, 2008.
38. Huang QH, Gumireddy K, Schrier M, etal: The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10: 202-210, 2008.
39. Negrini M and Calin GA: Breast cancer metastasis: a microRNA story. Breast Cancer Res 10: 203, 2008.
40. Yu F, Yao H, Zhu P, etal: Iet-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123, 2007.
41. + breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study. PLoS One 7: e36170, 2012.
42. Cortés-Sempere M and Ibáñez de Cáceres I: microRNAs as novel epigenetic biomarkers for human cancer. Clin Transl Oncol13: 357-362, 2011.
43. Adams BD, Furneaux H and White BA: The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 21: 1132-1147, 2007.
44. Kondo N, Toyama T, Sugiura H, Fujii Y and Yamashita H: miR-206 expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 68: 5004-5008, 2008.
45. Maillot G, Lacroix-Triki M, Pierredon S, etal: Widespread estrogen-dependent repression of microRNAs involved in breast tumor cell growth. Cancer Res 69: 8332-8340, 2009.
46. Pandey DP and Picard D: miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol 29: 3783-3790, 2009.
47. Xiong J, Yu D, Wei N, etal: An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J 277: 1684-1694, 2010.
48. Zhao JJ, Lin J, Yang H, etal: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283: 31079-31086, 2008.
49. Manavalan TT, Teng Y, Appana SN, etal: Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Cancer Lett313: 26-43, 2011.
50. Lau L, Chan K and Khoo U: Identification of microRNAs associated with tamoxifen resistance in breast cancer. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research (AACR) (abstract 2040), 2010.
51. Hossain A, Kuo MT and Saunders GF: Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 26: 8191-8201, 2006.
52. Adams BD, Claffey KP and White BA: Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Endocrinology150: 14-23, 2009.
53. Rao X, Di Leva G, Li M, etal: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30: 1082-1097, 2011.
54. Fan M, Yan PS, Hartman-Frey C, etal: Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66: 11954-11966, 2006.
55. Cittelly DM, Das PM, Spoelstra NS, etal: Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer 9: 317, 2010.
56. Lu Y, Roy S, Nuovo G, etal: Anti-microRNA-222 (anti-miR-222) and-181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 286: 42292-42302, 2011.
57. Lønning PE: Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer 45: 527-535, 2009.
58. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME and Jones FE: Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31: 2049-2057, 2010.
59. Frasor J, Chang EC, Komm B, etal: Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 66: 7334-7340, 2006.
60. Bergamaschi A and Katzenellenbogen BS: Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene 31: 39-47, 2012.
61. Sachdeva M, Wu H, Ru P, Hwang L, Trieu V and Mo Y: MicroRNA-101 promotes estrogen independent growth and confers tamoxifen resistance in ER positive breast cancer cells. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research (AACR) (abstract 2104), 2010.
62. Ji J, Shi J, Budhu A, etal: MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361: 1437-1447, 2009.
63. Murakami Y, Tanaka M, Toyoda H, etal: Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitisC. BMC Med Genomics 3: 48, 2010.
64. Rothé F, Ignatiadis M, Chaboteaux C, etal: Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 6: e20980, 2011.
65. Rodríguez-González FG, Sieuwerts AM, Smid M, etal: MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 127: 43-51, 2011.
66. Jansen MP, Reijm EA, Sieuwerts AM, etal: High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat 133: 937-947, 2012.
67. Mueller DW and Bosserhoff AK: Role of miRNAs in the progression of malignant melanoma. Br J Cancer 101: 551-556, 2009.
68. Kumar MS, Lu J, Mercer KL, Golub TR and Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39: 673-677, 2007.
69. Xi Y, Nakajima G, Gavin E, etal: Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13: 1668-1674, 2007.
70. Lawrie CH, Gal S, Dunlop HM, etal: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675, 2008.
71. Mitchell PS, Parkin RK, Kroh EM, etal: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
72. Chen X, Ba Y, Ma L, etal: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
73. Gilad S, Meiri E, Yogev Y, etal: Serum microRNAs are promising novel biomarkers. PLoS One 3: e3148, 2008.
74. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB and Liu S: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 5: e13735, 2010.
75. Hutvágner G, Simard MJ, Mello CC and Zamore PD: Sequence-specific inhibition of small RNA function. PLoS Biol 2: E98, 2004.
76. Meister G, Landthaler M, Dorsett Y and Tuschl T: Sequence-specific inhibition of microRNA-and siRNA-induced RNA silencing. RNA 10: 544-550, 2004.
77. Ørom UA, Kauppinen S and Lund AH: LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 372: 137-141, 2006.
78. Krützfeldt J, Rajewsky N, Braich R, etal: Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689, 2005.